An outpatient study to evaluate the safety and efficacy of cariprazine as adjunct to antidepressant therapy (ADT) in participants with major depressive disorder (MDD) who have an inadequate response to ADT alone. This clinical study compared cariprazine + ADT with placebo + ADT in outpatients with a diagnosis of MDD and an inadequate response to ADT. The study consisted of approximately 2 weeks of screening and washout followed by 8 weeks of double-blind treatment followed by a 1 week safety follow-up.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
819
Placebo was supplied in capsules
Cariprazine was supplied in capsules.
Change From Baseline in the Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score at Week 8
The MADRS is a clinician-rated scale to assess depressive symptomatology during the preceding week. Participants are rated on 10 items (feelings of sadness, lassitude, pessimism, inner tension, suicidality, reduced sleep or appetite, difficulty concentrating, and lack of interest) each on a 7-point scale from 0 (no symptoms) to 6 (symptoms of maximum severity). The total score ranges from 0 to 60 with a higher score indicating more depression. A negative change score indicates improvement.
Time frame: Baseline to Week 8
Change From Baseline in the Sheehan Disability Scale (SDS) Total Score at Week 8
The SDS measures an individual's perception of the extent to which his or her emotional symptoms are disrupting his or her functioning in 3 domains, work/school, social life/leisure activities, and family life/home responsibilities. The participant is asked to rate the degree to which their functioning is impaired on an 11-point scale, ranging from 0 (not at all) to 10 (extremely). Scores of 0 to 3 indicate mild functional impairment, 4 to 6 indicate moderate functional impairment, and 7 to 9 indicate marked functional impairment. The scores for the 3 domains are summed into a total score that ranges from 0 (unimpaired) to 30 (highly impaired). A higher score indicates greater impairment. A negative change score indicates improvement.
Time frame: Baseline to Week 8
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Forest Investigative Site 077
Garden Grove, California, United States
Forest Investigative Site 019
National City, California, United States
Forest Investigative Site 039
Oceanside, California, United States
Forest Investigative Site 015
Orange, California, United States
Forest Investigative Site 050
Orange, California, United States
Forest Investigative Site 008
Redlands, California, United States
Forest Investigative Site 066
Sherman Oaks, California, United States
Forest Investigative Site 063
Gainesville, Florida, United States
Forest Investigative Site 029
Jacksonville, Florida, United States
Forest Investigative Site 012
Kissimmee, Florida, United States
...and 62 more locations